StockNews.AI
UG
StockNews.AI
151 days

United-Guardian Reports 2024 Financial Results

1. UG net sales rose 12% to $12.18 million in FY 2024. 2. Net income increased by 26% to $3.25 million in 2024. 3. Cosmetics and medical lubricants sales grew significantly by 32% and 16%. 4. Pharmaceutical sales dropped 5% due to supply disruption in Renacidin. 5. Market demand in China has positively influenced UG's sales growth.

Earnings
-3.03%Current Return
VS
-0.27%S&P 500
$9.9103/21 09:05 AM EDTEvent Start
$9.6103/24 09:22 AM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

The strong growth in sales and income could boost investor confidence. Historical trends show that consistent growth often leads to price appreciation.

How important is it?

The reported financial results indicate strong performance, directly enhancing investor outlook. A marked increase in sales in key segments signals future growth prospects.

Why Short Term?

Immediate reactions in stock prices are likely due to the recent financial results. However, sustained growth will depend on continued market conditions and recovery of pharmaceutical sales.

Related Companies

SIALAPDPFEABBV
March 21, 2025 09:00 ET  | Source: United-Guardian, Inc. HAUPPAUGE, N.Y., March 21, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2024 increased compared to FY 2023. Net sales for the year increased by 12% from $10,885,154 in 2023 to $12,181,971 in 2024, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,581,370 ($0.56 per share) in 2023. Donna Vigilante, President of United-Guardian, stated, “We are pleased to announce that net sales and net income increased from 2023 to 2024. Sales of cosmetics ingredients and medical lubricants increased by 32% and 16%, respectively. The increase in cosmetic ingredient sales was primarily due to increased purchase orders from our largest distributor. Based on feedback from our distributor, the increase was due to greater demand for our products in China as a result of regaining market share at certain key accounts. The increase in medical lubricants was driven by greater demand from one of our large contract manufacturer customers in China. Pharmaceutical sales decreased by 5% in 2024, due to a supply disruption of Renacidin, our main pharmaceutical product, that we experienced at the end of 2023 and carried into the first quarter of 2024. This disruption impacted our sales of Renacidin for 2024. Sales began increasing once supply levels resumed, and we are hopeful that sales of Renacidin will return to their previous levels in 2025.” United-Guardian is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants. NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.  FINANCIAL RESULTS AS OF AND FOR THE YEARS ENDEDDECEMBER 31, 2024 AND 2023STATEMENTS OF INCOME   Years ended December 31,   2024  2023          Net sales $12,181,971  $10,885,154          Costs and expenses:        Cost of sales  5,721,584   5,479,566 Operating expenses  2,356,819   2,078,564 Research and development  456,779   463,992 Total costs and expenses  8,535,182   8,022,122 Income from operations  3,646,789   2,863,032 Other income:        Investment income  434,679   306,651 Net gain on marketable securities  26,989   81,095 Total other income   461,668   387,746          Income before provision for income taxes  4,108,457   3,250,778          Provision for income taxes  857,582   669,408 Net income $3,250,875  $2,581,370          Earnings per common share (basic and diluted) $0.71  $0.56          Weighted average shares (basic and diluted)  4,594,319   4,594,319           BALANCE SHEET DATA(condensed)   December 31,  2024   2023 Current assets:$12,665,551  $12,252,713 Deferred income taxes, net 175,397   50,930 Property, plant, and equipment, net 956,387   619,195 Total assets 13,797,335   12,922,838         Current liabilities: 1,914,469   1,534,256 Total liabilities 1,914,469   1,534,256         Stockholders’ equity 11,882,866     11,388,582 Total liabilities and stockholders’ equity$13,797,335  $12,922,838 

Related News